levoleucovorin and Malaria--Falciparum

levoleucovorin has been researched along with Malaria--Falciparum* in 2 studies

Other Studies

2 other study(ies) available for levoleucovorin and Malaria--Falciparum

Article	Year
The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. The American journal of tropical medicine and hygiene, 1999, Volume: 60, Issue:6 We have studied the reversal of activity against Plasmodium falciparum of WR99210, a triazine antimalarial drug, and of the pro-drug PS-15 by folic acid (FA) and folinic acid (FNA). Folic acid and FNA inhibit the growth of P. falciparum in vitro at concentrations > 10(-4.5) and 10(-3.5) mol/L, respectively. The activity of pyrimethamine against Kenyan strains M24 and K39 is reduced 10-12-fold by 10(-5) mol/L of FA, and virtually eliminated by 10(-5) mol/L of FNA. Folates do not antagonise the action of WR99210 against Kenyan strains, and only partially antagonize the action of WR99210 action against the Southeast Asian strains V1/S and W282. Similarly, FA and FNA exerted weak or no antagonism of the action of PS-15. The inability of folates to antagonize the action of WR99210 can be explained in terms of high drug-enzyme affinity, but this does not account for the inability of FA and FNA to antagonize PS-15. These results suggest that action of PS-15 against P. falciparum is primarily due to a non-folate mechanism. Topics: Animals; Antidotes; Antimalarials; Asia, Southeastern; Dose-Response Relationship, Drug; Drug Resistance; Folic Acid; Folic Acid Antagonists; Hematinics; Humans; Inhibitory Concentration 50; Kenya; Leucovorin; Malaria, Falciparum; Plasmodium falciparum; Prodrugs; Proguanil; Triazines	1999
Treatment of hyperreactive malarial splenomegaly syndrome. Lancet (London, England), 1994, Jun-04, Volume: 343, Issue:8910 Topics: Adult; Female; Humans; Leucovorin; Malaria, Falciparum; Male; Pyrimethamine; Splenomegaly; Syndrome	1994

Article

Year

The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug.

The American journal of tropical medicine and hygiene, 1999, Volume: 60, Issue:6

We have studied the reversal of activity against Plasmodium falciparum of WR99210, a triazine antimalarial drug, and of the pro-drug PS-15 by folic acid (FA) and folinic acid (FNA). Folic acid and FNA inhibit the growth of P. falciparum in vitro at concentrations > 10(-4.5) and 10(-3.5) mol/L, respectively. The activity of pyrimethamine against Kenyan strains M24 and K39 is reduced 10-12-fold by 10(-5) mol/L of FA, and virtually eliminated by 10(-5) mol/L of FNA. Folates do not antagonise the action of WR99210 against Kenyan strains, and only partially antagonize the action of WR99210 action against the Southeast Asian strains V1/S and W282. Similarly, FA and FNA exerted weak or no antagonism of the action of PS-15. The inability of folates to antagonize the action of WR99210 can be explained in terms of high drug-enzyme affinity, but this does not account for the inability of FA and FNA to antagonize PS-15. These results suggest that action of PS-15 against P. falciparum is primarily due to a non-folate mechanism.

Topics: Animals; Antidotes; Antimalarials; Asia, Southeastern; Dose-Response Relationship, Drug; Drug Resistance; Folic Acid; Folic Acid Antagonists; Hematinics; Humans; Inhibitory Concentration 50; Kenya; Leucovorin; Malaria, Falciparum; Plasmodium falciparum; Prodrugs; Proguanil; Triazines

1999

Treatment of hyperreactive malarial splenomegaly syndrome.

Lancet (London, England), 1994, Jun-04, Volume: 343, Issue:8910

Topics: Adult; Female; Humans; Leucovorin; Malaria, Falciparum; Male; Pyrimethamine; Splenomegaly; Syndrome

1994